Biotech News

PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering

PureTech Health (PRTC)PureTech Health2026-04-13 06:00 ESTFinancing

RNS Number: 1579A PureTech Health PLC 13 April 2026 13 April 2026 PureTech Health plc PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (" PureTech " or the "Company"), a

PureTech Health

Founded-Entity Model PureTech Health creates and advances biotechnology companies around internally identified scientific concepts. Rather than operating as a conventional single-pipeline developer, it retains ownership interests and economic rights across a portfolio of independently financed founded entities. Celea Therapeutics Celea...

Recent company news

PRTCPureTech Health2026-07-13 06:00 EST

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-07-02 06:01 EST

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-07-02 06:00 EST

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PRTCPureTech Health2026-06-10 16:38 EST

Results of Annual General Meeting

PRTCPureTech Health2026-06-09 06:00 EST

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

Close: 17.42 USD
Market cap: 424.03M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering

Related news

PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Health

Recent company news

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

Results of Annual General Meeting

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

PureTech Health Founded Entity Seaport Therapeutics Files Registration Statement for Proposed Initial Public Offering

Related news

PureTech Founded Entity Seaport Therapeutics Announces Pricing of Upsized Initial Public Offering

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Health

Recent company news

PureTech Founded Entity Celea Therapeutics Doses First Patient in Global Phase 3 SURPASS-IPF Trial Evaluating Deupirfenidone for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

PureTech Announces Completion of $180 Million Financing for Founded Entity Celea Therapeutics to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)

Results of Annual General Meeting

PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers

Stock data

PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)